Loading
A phase 2 trial of Pembrolizumab, Cyclophosphamide in diffuse large b-cell lymphoma, run by ImmunoVaccine Technologies, Inc. (IMV Inc.), now recruiting.
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT04920617 by ImmunoVaccine Technologies, Inc. (IMV Inc.), with 102 participants planned, started 2021-06-18 and due to reach its primary completion in 2024-10. Interventions recorded: DPX-Survivac, Pembrolizumab, CPA. Conditions listed: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.